TSRA-196

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameTSRA-196

Drug Alias Namein vivo target-primed reverse transcription genome editing product consisting of two chemically modified RNA drug substances: a messenger RNA, and a template guide RNA formulated in a lipid nanoparticle delivery vehicle comprised of 4 lipids to target the pathogenic PiZ allele in the SERPINA1 geneTSRA-196

ClassificationCell and gene therapy > Gene therapy > Gene editingCell and gene therapy > Gene therapy > LNP

Mechanisms of ActionAlpha-1-antiproteinase modulators

TargetsAlpha-1-antiproteinase

Therapy Area/Indicationsalpha 1-Antitrypsin Deficiency

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustralia

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesTessera Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesRegeneron Pharmaceuticals Inc Tessera Therapeutics Inc

Inactive CompaniesN/A

Active Indicationsalpha 1-Antitrypsin Deficiency

Inactive IndicationsN/A

Other Information

ATC CodeN/A